Needham Maintains Buy on Medtronic, Lowers Price Target to $101

Benzinga Newsdesk www.benzinga.com Negative 59.1%

Neg 59.1% Neu 0% Pos 0%

Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and lowers the price target from $120 to $101.

Comments

No comments yet. Be the first!